Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 6333

Next Previous
Drug Profile

RG 6333

Alternative Names: CD19 X CD28 - Roche; RG-6333; RO-7443904

Latest Information Update: 17 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action CD19 antigen modulators; CD28 antigen modulators; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Dec 2024 The efficacy, adverse event, pharmacokinetics and pharmacodynamics data from a phase I trial in Non-Hodgkin's lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 16 Aug 2024 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in Australia, USA, Denmark, France, Italy, United Kingdom (SC) (Roche pipeline, August 2024)
  • 16 Aug 2024 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in United Kingdom, Italy, France, Denmark, USA, Australia (IV) (Roche pipeline, August 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top